CRISP-HR Therapeutics Revenue and Competitors

At CRISP-HR Therapeutics, our goal is develop technology to allow non-toxic, high efficiency error-free genetic engineering at any site, of any size, in any genome, and in any organism. CRISPR/Cas9 is an innovative and powerful tool for editing genomic DNA. Unfortunately, first generation platforms have yet to fulfill on their promise, as issues with cellular toxicity and genomic editing efficiency have significantly limited their usefulness. This is especially true for therapeutic applications, which have limited treatment indications and sub-optimal outcomes. At CRISP-HR Therapeutics, we have addressed these limitations by developing a next generation CRISPR based genetic engineering platform: Cas9-HR. Cas9-HR directs cells to use error-free rather than error-prone pathways, which we have demonstrated can dramatically decrease cellular toxicity while simultaneously increasing error-free editing efficiency. Ultimately, we believe our Cas9-HR platform solves major problems plaguing first generation CRISPR/Cas9 systems. We look forward to developing a wide variety of cellular therapeutics using the platform, to improve patient outcomes, quality of life, and overall human wellbeing.